Physician profile
Karin Dimon
NPI 1780669176
$580.25
in general payments reported to CMS, 2019-2025
12 companies · $19.32 in 2025
The $19.32 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.10 · 2021: $15.31 · 2023: $282 · 2024: $230 · 2025: $19.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $206.63 | 2023 | Myrisk |
| Coopersurgical, INC. | $101.53 | 2023-2024 | Paragard T 380a, Endosee, Paragard T 380a |
| Shield Therapeutics INC | $50.73 | 2023-2024 | Accrufer |
| Astellas Pharma US INC | $47.43 | 2024 | Veozah |
| Exeltis, USA INC. | $40.95 | 2023-2025 | Slynd |
| Agile Therapeutics, INC. | $31.19 | 2024 | Twirla |
| Abbvie INC. | $26.55 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Covidien Lp | $20.28 | 2019 | |
| Axonics, INC. | $15.31 | 2021 | |
| Minerva Surgical, INC | $13.84 | 2024 | |
| Aspira Women'S Health INC | $13.12 | 2024 | Ova1 |
| Bayer Healthcare Pharmaceuticals INC. | $12.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Dimon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.